Shahana Sharmin1, Fatima Tuj Zohura2,3, Md Sajedul Islam2,4, Anika Shimonty1, Md Abdullah-Al-Kamran Khan2,5, Rehana Parveen6, Foujia Sharmin7, Chowdhury Rafiqul Ahsan1, Abul Bashar Mir Md Khademul Islam2, Mahmuda Yasmin8. 1. Department of Microbiology, University of Dhaka, Dhaka, Bangladesh. 2. Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh. 3. Current Affiliation: Internal Medicine OPD, Bangabandhu Sheikh Mujib Medical University Hospital, Dhaka, Bangladesh. 4. Current Affiliation: Department of Biochemistry and Biotechnology, University of Barisal, Barisal, Bangladesh. 5. Current Affiliation Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh. 6. Square Hospital, Dhaka, Bangladesh. 7. Department of Gynecological Oncology, National Institute of Cancer Research & Hospital, Dhaka, Bangladesh. 8. Department of Microbiology, University of Dhaka, Dhaka, Bangladesh. yasmin@du.ac.bd.
Abstract
BACKGROUND: Cervical cancer is a gynecologic cancer type that develops in the cervix, accounting for 8% mortality of all female cancer patients. Infection with specific human papillomavirus (HPV) types is considered the most severe risk factor for cervical cancer. In the context of our socioeconomic conditions, an increasing burden of this disease and high mortality rate prevail in Bangladesh. Although several researches related to the epidemiology, HPV vaccination, and treatment modalities were conducted, researches on the mutation profiles of marker genes in cervical cancer in Bangladesh remain unexplored. METHODS: In this study, five different genomic regions within the top three most frequently mutated genes (EGFR, KRAS and PIK3CA) in COSMIC database with a key role in the development of cervical cancers were selected to study the mutation frequency in Bangladeshi patients. In silico analysis was done in two steps: nucleotide sequence analysis and its corresponding amino acid analysis. RESULTS: DNA from 46 cervical cancer tissue samples were extracted and amplified by PCR, using 1 set of primers designed for EGFR and 2 sets of primers designed for two different regions of both PIK3CA and KRAS gene. In total, 39 mutations were found in 26 patient samples. Eleven different mutations (23.91%), twenty-four different mutations (52.17%) and four mutations (8.7%) were found in amplified EGFR, PIK3CA and KRAS gene fragments, respectively; among which 1 (EGFR) was common in seven patient samples and 2 (PIKCA) were found in more than 1 patient. Our study shows that except for KRAS, the frequency of observed mutations in our patients is higher than those reported earlier in other parts of the world. Most of the exonic mutations were found only in the PIK3CA and EGFR genes. CONCLUSIONS: The study can be used as a basis to build a mutation database for cervical cancer in Bangladesh with the possibility of targetable oncogenic mutations. Further explorations are needed to establish future diagnostics, personalized medicine decisions, and other pharmaceutical applications for specific cancer subtypes.
BACKGROUND:Cervical cancer is a gynecologic cancer type that develops in the cervix, accounting for 8% mortality of all female cancerpatients. Infection with specific human papillomavirus (HPV) types is considered the most severe risk factor for cervical cancer. In the context of our socioeconomic conditions, an increasing burden of this disease and high mortality rate prevail in Bangladesh. Although several researches related to the epidemiology, HPV vaccination, and treatment modalities were conducted, researches on the mutation profiles of marker genes in cervical cancer in Bangladesh remain unexplored. METHODS: In this study, five different genomic regions within the top three most frequently mutated genes (EGFR, KRAS and PIK3CA) in COSMIC database with a key role in the development of cervical cancers were selected to study the mutation frequency in Bangladeshi patients. In silico analysis was done in two steps: nucleotide sequence analysis and its corresponding amino acid analysis. RESULTS: DNA from 46 cervical cancer tissue samples were extracted and amplified by PCR, using 1 set of primers designed for EGFR and 2 sets of primers designed for two different regions of both PIK3CA and KRAS gene. In total, 39 mutations were found in 26 patient samples. Eleven different mutations (23.91%), twenty-four different mutations (52.17%) and four mutations (8.7%) were found in amplified EGFR, PIK3CA and KRAS gene fragments, respectively; among which 1 (EGFR) was common in seven patient samples and 2 (PIKCA) were found in more than 1 patient. Our study shows that except for KRAS, the frequency of observed mutations in our patients is higher than those reported earlier in other parts of the world. Most of the exonic mutations were found only in the PIK3CA and EGFR genes. CONCLUSIONS: The study can be used as a basis to build a mutation database for cervical cancer in Bangladesh with the possibility of targetable oncogenic mutations. Further explorations are needed to establish future diagnostics, personalized medicine decisions, and other pharmaceutical applications for specific cancer subtypes.
Authors: H Arias-Pulido; N Joste; A Chavez; C Y Muller; D Dai; H O Smith; C F Verschraegen Journal: Int J Gynecol Cancer Date: 2007-10-19 Impact factor: 3.437
Authors: Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch Journal: Cancer Date: 2013-08-23 Impact factor: 6.860
Authors: William McLaren; Laurent Gil; Sarah E Hunt; Harpreet Singh Riat; Graham R S Ritchie; Anja Thormann; Paul Flicek; Fiona Cunningham Journal: Genome Biol Date: 2016-06-06 Impact factor: 13.583
Authors: John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971